Patients With Distinct BRAF-mutant Melanoma Genotypes May Differentially Respond to Targeted and Immunologic Therapies
PHILADELPHIA – Unlike patients with melanoma bearing BRAF V600E mutations, those whose tumors have V600K mutations may benefit less...